| Literature DB >> 33539754 |
Renée L Mulder1, Anna Font-Gonzalez2, Daniel M Green3, Erik A H Loeffen4, Melissa M Hudson3, Jacqueline Loonen5, Richard Yu6, Jill P Ginsberg7, Rod T Mitchell8, Julianne Byrne9, Roderick Skinner10, Antoinette Anazodo11, Louis S Constine12, Andrica de Vries13, Kirsi Jahnukainen14, Armando Lorenzo15, Andreas Meissner16, Leena Nahata17, Marij Dinkelman-Smit18, Herman Tournaye19, Riccardo Haupt20, Marry M van den Heuvel-Eibrink13, Hanneke M van Santen21, Ans M M van Pelt22, Uta Dirksen23, Jaap den Hartogh24, Eline van Dulmen-den Broeder25, W Hamish Wallace26, Jennifer Levine27, Wim J E Tissing28, Leontien C M Kremer2, Lisa B Kenney6, Marianne D van de Wetering29.
Abstract
Male patients with childhood, adolescent, and young adult cancer are at an increased risk for infertility if their treatment adversely affects reproductive organ function. Future fertility is a primary concern of patients and their families. Variations in clinical practice are barriers to the timely implementation of interventions that preserve fertility. As part of the PanCareLIFE Consortium, in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in male patients who are diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. Recognising the need for global consensus, this clinical practice guideline used existing evidence and international expertise to rigorously develop transparent recommendations that are easy to use to facilitate the care of male patients with childhood, adolescent, and young adult cancer who are at high risk of fertility impairment and to enhance their quality of life.Entities:
Year: 2021 PMID: 33539754 DOI: 10.1016/S1470-2045(20)30582-9
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316